Day: May 15, 2024

Increase in total revenues of 105% year-over-year 17% point increase in net margin, adjusted for stock option expense Cash and cash equivalents of $2.1 million as of April 1st, unchanged from December 31st, 2023LAS VEGAS, May 15, 2024 (GLOBE NEWSWIRE) — Jet.AI Inc. (the “Company”) (Nasdaq: JTAI), an innovative private aviation and artificial intelligence (“AI”) company, today announced financial results for the first quarter ended March 31, 2024. First Quarter 2024 and Recent Operational HighlightsReleased the National Jet Card Program using third party aircraft Announced partnership with FL3XX to integrate its DynoFlight carbon removal platform making it an easy option for thousands of FL3XX customers Launched Reroute AI, a web-based software tool designed to transform the way empty flight legs are utilized As previously...

Midland, Texas, May 15, 2024 (GLOBE NEWSWIRE) — Natural Gas Services Group, Inc. (“NGS” or the “Company”) (NYSE:NGS), a leading provider of natural gas compression equipment, technology and services to the energy industry, today announced financial results for the three months ended March 31, 2024. First Quarter 2024 HighlightsRental revenue of $33.7 million, an increase of 48% when compared to the first quarter of 2023 and 7% when compared to the fourth quarter of 2023. Net income of $5.1 million, or $0.41 per basic share, as compared to a net income of $0.4 million, or $0.03 per basic share in the first quarter of 2023 and net income of $1.7 million, or $0.14 per basic share in the fourth quarter of 2023. Adjusted EBITDA of $16.9 million, compared to $7.8 million in the first quarter of 2023 and $16.3 million in the fourth...

Reported Full Year 2023 total revenues of 2% growth at €48.5 million Secured approximately USD 20 million – strengthening cash position and expanding relationship with Lifera, a biopharma company owned by the PIF Positioned for strong performance in 2024, driven by new and existing Pharma business and solid Diagnostic growth in line with industry standards; guidance of FY2024 total revenue growth between 10-15% Ongoing strategic alternatives process focused on sustainable long-term value creation for the benefit of its stakeholdersCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December...

First Quarter 2024 Highlighted by Total Revenue Growth of 4% to $19.5 Million NEW PORT RICHEY, Fla., May 15, 2024 (GLOBE NEWSWIRE) — Zeo Energy Corp. (Nasdaq: ZEO) (“Zeo”, “Zeo Energy”, or the “Company”), a leading Florida-based provider of residential solar and energy efficiency solutions, today reported financial results for the first quarter ended March 31, 2024. Recent Financial and Operational HighlightsTotal revenue for the first quarter 2024 increased 4% to $19.5 million year-over-year Gross profit for the first quarter 2024 decreased 47% to $1.8 million year-over-year Adjusted EBITDA for the first quarter 2024 resulted in a loss of $1.2 million Completed merger with ESGEN Acquisition Corp. on March 13, 2024 (the “Business Combination”), resulting in shares and warrants trading on the Nasdaq Capital Market under the...

Q1 2024 Total Revenue increased 145% Y/Y and 34% Q/Q Q1 Co-Location Business Revenue increased 90% Y/Y and 83% Q/Q Q1 Energy Management Business Revenue increased 461% Y/Y and 2% Q/Q Company optimized and reduced Q1 SG&A expenses by 30% Y/Y and 19% Q/Q MIDLAND, Pa., May 15, 2024 (GLOBE NEWSWIRE) — Mawson Infrastructure Group Inc. (NASDAQ: MIGI) (“Mawson”, “the Company”), a digital infrastructure company, today announced its unaudited financial and operational results for the first quarter of fiscal year 2024 ended March 31, 2024. “We are delighted with the overall revenue increase during the first quarter of 2024 —145% year-on-year growth and 34% quarter-on-quarter growth, in addition to our progressing the Company’s strategic, operational, and technological plans in Q1, 2024,” said Rahul Mewawalla, CEO and President of Mawson....

Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated Topline results from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) expected in the third quarter of 2024 AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) — Aileron Therapeutics, Inc. (“Aileron” or the “Company”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the first quarter ended March 31, 2024, and provided a business update. “In the first quarter, we made steady progress against our key priorities of advancing LTI-03 and generating data from Cohort 1 in IPF,”...

AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the first quarter of 2024. Recent Company HighlightsMTEM presented clinical data at the 2024 AACR Annual Meeting that demonstrated MT-6402’s tolerable safety and promising efficacy profile in relapsed/refractory HNSCC patients. As monotherapy in 7 evaluable HNSCC patients (all heavily pretreated and checkpoint experienced), 2 confirmed PRs (ongoing at 10 and 20 months, respectively) and 4 SDs (two of whom showed...

NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) —  XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), an authority in wellness solutions for people on the go, today reported results for the first quarter ended March 31, 2024. Recent Highlights:XWELL delivered 2024 first quarter revenue growth of approximately 24% from the 2023 first quarter. The Company has reduced its cost structure, simplified its processes, and has maintained continued momentum on its path to profitability. The following demonstrates the positive effects of XWELL’s actions to enhance its business model:Total cost of sales decreased approximately 7% from the 2023 first quarter. General and administrative expenses decreased approximately 47% from the 2023 first quarter. Total operating expenses decreased approximately 26% from the 2023...

NEWPORT BEACH, Calif., May 15, 2024 (GLOBE NEWSWIRE) — Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today reported financial results for the first quarter ended March 31, 2024. Elevai Labs CEO, Jordan R. Plews, PhD stated, “This quarter, Elevai Labs has demonstrated remarkable year-over-year revenue growth while significantly improving our gross margin, reflecting our commitment to optimizing production and stringent cost management. We remain focused on sustainable growth while enhancing our operational efficiencies and continuing to invest in innovation. These results underscore our adaptability and strategic foresight in meeting market demands.” Financial Results for the Three Months Ended March 31, 2024Revenue increased to $614,563 for the three months...